Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial

International Journal of Infectious Diseases

Volumn 9, Issue 5, 2005, Pages 251-261

  Sacchidanand, Sarvajna ^a   Penn, Robert L ^b   Embil, John M ^c   Campos, Maria E ^d   Curcio, Daniel ^e   Ellis Grosse, Evelyn ^f   Loh, Evan ^f   Rose, Gilbert ^f  

^a Victoria Hospital   (India)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

^d Hospital de Urgencia y Asistencia Pública Dr Alejandro Del Río   (Chile)

^e Sanatorio Guemes   (Argentina)

^f PFIZER INC   (United States)

Author keywords

Efficacy; Glycylcycline; Safety; Skin structure infection; Tigecycline

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ASPARTATE AMINOTRANSFERASE; AZTREONAM; BETA LACTAM ANTIBIOTIC; GLYCYLCYCLINE DERIVATIVE; LACTATE DEHYDROGENASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CARDIOVASCULAR SYMPTOM; CHILL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEATH; DIARRHEA; DIGESTIVE SYSTEM DISEASE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DYSPEPSIA; DYSPNEA; FEMALE; FEVER; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; INFECTION; INSOMNIA; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHATIC SYSTEM; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PAIN; PARTIAL THROMBOPLASTIN TIME; PHASE 3 CLINICAL TRIAL; PHLEBITIS; PHYSICAL EXAMINATION; PROTHROMBIN TIME; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY FUNCTION DISORDER; SCREENING; SIDE EFFECT; SKIN DISEASE; SKIN INFECTION; SKIN STRUCTURE; THROMBOCYTOPENIA; UROGENITAL TRACT DISEASE; VOMITING;

ANTI-BACTERIAL AGENTS; AZTREONAM; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GRAM-POSITIVE COCCI; HUMANS; INDIA; INJECTIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; NAUSEA; NORTH AMERICA; SKIN DISEASES, BACTERIAL; SOUTH AMERICA; STREPTOCOCCUS PYOGENES; TREATMENT OUTCOME; VANCOMYCIN; VOMITING;

EID: 23944505501     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2005.05.003     Document Type: Article

References (35)

1. A.L. Bisno Cutaneous infections: microbiologic and epidemiologic considerations Am J Med 76 1984 172 179
2. R.N. Jones, D.E. Low, and M.A. Pfaller Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: the role of streptogramins and other newer compounds Diagn Microbiol Infect Dis 33 1999 101 112
3. CDC. Background on antibiotic resistance, 2004. Available at: http://www.cdc.gov/drugresistance/community/
4. B. Spellberg, J.H. Powers, E.P. Brass, L.G. Miller, and J.E. Edwards Jr. Trends in antimicrobial drug development: implications for the future Clin Infect Dis 38 2004 1279 1286
5. P.E. Sum, and P. Petersen Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936 Bioorg Med Chem Lett 9 1999 1459 1462
6. S.J. Projan Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent Pharmacotherapy 20 9 Pt 2 2000 219S 223S discussion 224S-228S
7. I. Chopra Glycylcyclines: third-generation tetracycline antibiotics Curr Opin Pharmacol 1 2001 464 469
8. D. Milatovic, F.-J. Schmitz, J. Verhoef, and A.C. Fluit Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates Antimicrob Agents Chemother 47 2003 400 404
9. T. Hirata, A. Saito, K. Nishino, N. Tamura, and A. Yamaguchi Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936) Antimicrob Agents Chemother 48 2004 2179 2184
10. D.J. Biedenbach, M.L. Beach, and R.N. Jones In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant Gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases Diagn Microbiol Infect Dis 40 2001 173 177
11. Betriu C, Culebras E, Gomez M, Rodriguez-Avail I, Picazo JJ. In vitro activity of tigecycline against Bacteroides species. ICAAC 2004. 30 October-2 November, 2004. Washington DC, USA.
12. R.G. Postier, S.L. Green, S.R. Klein, E.J. Ellis-Grosse, and E. Loh Tigecycline-200 Study Group. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients Clin Ther 26 2004 704 714
13. P.J. Petersen, N.V. Jacobus, W.J. Weiss, P.E. Sum, and R.T. Testa In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936) Antimicrob Agents Chemother 43 1999 738 744
14. A.C. Gales, and R.N. Jones Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates Diagn Microbiol Infect Dis 36 2000 19 36
15. P.J. Petersen, P.A. Bradford, W.J. Weiss, T.M. Murphy, P.E. Sum, and S.J. Projan In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens Antimicrob Agents Chemother 46 2002 2595 2601
16. MedicalEconomics. Vancocin® HCl. Sterile vancomycin hydrochloride; intravenous. 55th ed. Montvale, NJ, 2001.
17. MedicalEconomics. Azactam®. Aztreonam for injection. 55th ed. Montvale, NJ, 2001.
18. NCCLS. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard-fifth ed. Wayne, PA, 2001.
19. NCCLS. Performance standards for antimicrobial disk susceptibility tests; approved standard-eighth ed. Wayne, PA, 2003: NCCLS document M2-A8.
20. NCCLS. Methods for dilution antimicrobial susceptibility tests for microbes that grow aerobically; approved standard-sixth ed. Wayne, PA, 2003: NCCLS document M7-A6.
21. A.T. Ghoneim, J. McGoldrick, P.W. Blick, M.W. Flowers, A.K. Marsden, and D.H. Wilson Aerobic and anaerobic bacteriology of subcutaneous abscesses Br J Surg 68 1981 498 500
22. M.E. Jones, F.J. Schmitz, A.C. Fluit, J. Acar, R. Gupta, and J. Verhoef Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an International Surveillance Programme. SENTRY Participants Group Eur J Clin Microbiol Infect Dis 18 1999 403 408
23. S. Kontiainen, and E. Rinne Bacteria isolated from skin and soft tissue lesions Eur J Clin Microbiol 6 1987 420 422
24. C.G. Mayhall The epidemiology of burn wound infections: then and now Clin Infect Dis 37 2003 543 550
25. M.N. Swartz Clinical practice. Cellulitis N Engl J Med 350 2004 904 912
26. H. Shmuely, S. Pitlik, M. Drucker, Z. Samra, H. Konisberger, and L. Leibovici Prediction of mortality in patients with bacteremia: the importance of pre-existing renal insufficiency Renal Failure 22 2000 99 108
27. E.B. Wilson Probable inference, the law of succession, and statistical inference J Am Stat Assn 22 1927 209 212
28. C.J. Clopper, and E.S. Pearson The use of confidence or fiducial limits illustrated in the case of the binomial Biometrika 26 1934 404 413
29. G. Muralidharan, J. Getsy, P. Mayer, I. Paty, M. Micalizzi, and J. Speth Pharmacokinetics (PK), safety and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother. 39 1999 303
30. H.B. Fung, J.Y. Chang, and S. Kuczynski A practical guide to the treatment of complicated skin and soft tissue infections Drugs 63 2003 1459 1480
31. L.J. Eron, B.A. Lipsky, D.E. Low, D. Nathwani, A.D. Tice, and G.A. Volturo Managing skin and soft tissue infections: expert panel recommendations on key decision points J Antimicrob Chemother 52 Suppl 1 2003 i3 i17
32. R.P. Rennie, R.N. Jones, and A.H. Mutnick Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: Report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000) Diagn Microbiol Infect Dis 45 2003 287 293
33. C.J. Henwood, T. Gatward, M. Warner, D. James, M.W. Stockdale, and R.P. Spence Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936) J Antimicrob Chemother 49 2002 479 487
34. C. Betriu, E. Culebras, I. Rodriguez-Avial, M. Gomez, B.A. Sanchez, and J.J. Picazo In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance Antimicrob Agents Chemother 48 2004 323 325
35. E.J.C. Goldstein, D.M. Citron, C.V. Merriam, Y. Warren, and K. Tyrrell Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens Antimicrob Agents Chemother 44 2000 2747 2751